TABLE 1.
Characteristics of the depressed cohort (N = 438,534) and sub‐cohort who received a single‐gene CYP2D6 or CYP2C19 test within 365 days of their index depression episode (n = 1795)
| Characteristic | Depression cohort (n = 438,534) | Received a single‐gene CYP2D6 or CYP2C19 test within 365 days (n = 1795) |
|---|---|---|
| Age (years) | ||
| Mean (SD), median | 43.2 (15.8), 43 | 42.2 (14.3), 41 |
| Min–max | 18–84 | 18–83 |
| 18–44, n (%) | 158,884 (36.2) | 664 (37.0) |
| 45–64, n (%) | 173,353 (39.5) | 759 (42.3) |
| 65+, n (%) | 106,297 (24.3) | 372 (20.7) |
| Women, n (%) | 291,772 (66.5) | 1159 (64.6) |
| Region, n (%) | ||
| East | 78,980 (18.0) | 139 (7.7) |
| Midwest | 141,898 (32.4) | 585 (32.6) |
| South | 84,476 (19.0) | 540 (30.1) |
| West | 134,183 (30.6) | 531 (29.6) |
| Insurance type, n (%) | ||
| Commercial | 265,696 (60.6) | 638 (35.4) |
| Managed Medicare/Medicaid | 164,588 (37.5) | 1134 (63.2) |
| Other/unknown | 8250 (1.9) | 23 (1.3) |
| Depression treatment within 365 days | ||
| Filled an antidepressant, n (%) | 210,129 (47.9) | 1059 (59.0) |
| Filled another psychotropic, n (%) | 118,466 (27.0) | 959 (53.4) |
| Anxiolytic | 90,094 (20.5) | 750 (41.8) |
| Antipsychotic/mood stabilizer | 27,417 (6.2) | 389 (21.7) |
| Stimulant | 19,719 (4.5) | 143 (8.0) |